# Characterizing antimicrobial selection pressure on resistance across four major causes of infections: Insights from the US Veterans Affairs Healthcare System, 2007-2021

Thi Mui Pham, PhD[1,2,5], Yue Zhang, PhD[3], McKenna Nevers, MS[3,4], Haojia Li, MS[3], Karim Khader, PhD[3,4], Yonatan H. Grad, MD, Prof[2,5,*], Matthew Samore, MD, Prof[3,4,*], Marc Lipsitch, DPhil, Prof[1,2,*]

[1] Department of Epidemiology, Harvard T.H. Chan School of Public Health
[2] Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health
[3] Department of Internal Medicine, Division of Epidemiology, Spencer Fox Eccles School of Medicine, University of Utah,
[4] IDEAS Center of Innovation, Veterans Affairs Salt Lake City Health Care System, Salt Lake City, Utah
[5] Department of Immunology and Infectious diseases, Harvard T.H. Chan School of Public Health
* co-senior authors

Corresponding author: Thi Mui Pham, Department of Epidemiology and Center for Communicable Disease Dynamics, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, 02115 Boston, MA, USA, tmpham@hsph.harvard.edu

## Abstract (340 words)
### Background
Systematic evidence on the extent to which antimicrobials select for antimicrobial resistance (AMR) is lacking. We quantified the effect of inpatient antibiotic use (AU) on AMR in four major pathogens across U.S. Veterans Affairs Medical Centres (VAMC).

### Methods
We analysed clinical microbiology isolates of *Staphylococcus aureus, Escherichia coli, Klebsiella pneumoniae,* and *Pseudomonas aeruginosa* collected at 138 VAMC across the USA from Feb 1, 2007 to Dec 31, 2021. Antibiotic use (AU) was measured as days of therapy per 1000 patient-days; multidrug resistance as number of isolates with resistant phenotypes per 1,000 admissions. Temporal trends were modelled using generalized estimating equations and average annual percentage changes (AAPC). Multilevel multinomial logistic regression related facility-level AU to the odds of resistant phenotypes, adjusting for calendar year, facility characteristics, and community prevalence. Phenotypes susceptible to key antibiotics served as the reference.

### Findings
From 2007 to 2021, hospital-onset infection incidence declined for all pathogens except for third-generation cephalosporins (3GC)-resistant *E. coli*. Overall, AU remained stable or decreased, except 3GC prescribing, which increased from 2007 until 2019 (AAPC 2·4%, 95% CI 1·3–3·5). Higher facility-level use of an antimicrobial increased the odds of corresponding resistant phenotypes, with some exceptions. Fluoroquinolones (FQLs) consistently selected for resistance across all four pathogens. In *S aureus*, each additional 14-day course of FQLs (per 1,000 patient-days) was linked to a 5.9% (95% CI: 0.8%-11.2%) increase in the relative odds of isolating FQL-resistant, macrolide-susceptible, methicillin-resistant *S aureus*. Anti-staphylococcal beta-lactams were not linked to methicillin-resistant *S aureus*. For Enterobacterales species, each additional 14-day course of 3GCs increased the odds of isolating 3GC- and beta-lactam/beta-lactamase-resistant *E coli* by 7.4% (95% CI: 1.8%-13.4%) and *K pneumoniae* by 4.1% (95% CI: 0.0%-8.7%). Each additional 14-day course of carbapenems increased the odds of carbapenem-resistant, FQL- and 3GC-susceptible *P aeruginosa* by 22.6% (95% CI: 13.4%-32.7%).

### Interpretation
FQLs play a key role in selecting for resistance across multiple pathogens. Increased 3GC prescribing offset reductions in FQLs and was associated with co-resistance in *E coli*. These findings underscore the need for comprehensive stewardship that coordinate strategies across multiple antimicrobials in tandem rather than in isolation.

**Introduction** (653 words)

Antimicrobial use has long been recognized as a major driver of antimicrobial resistance (AMR).[1] However, our understanding of the complex relationship between antimicrobial use and resistance remains incomplete, partly because of methodological challenges in assessing this association.[2] Many studies have demonstrated ecological correlations for single pathogen-single antimicrobial combinations at regional, national, or international scales.[3–11] In these studies, the evidence linking use to resistance is often contradictory, with some studies showing significant correlations for certain pathogens, while others reveal no clear association, particularly for commensal bacteria.[3–6] A landmark study of 26 European countries used data from 1997 to 2002 and correlated the use of β-lactams and fluoroquinolones with resistance in *Streptococcus pneumoniae, S. pyogenes*, and *Escherichia coli* isolates.[7] The study showed that nations with the highest outpatient antimicrobial consumption had the greatest prevalence of antimicrobial-resistant bacteria, whereas low-consumption countries had much lower resistance rates. In the United States, cross-sectional analyses have similarly examined multiple pathogen-antimicrobial pairs.[3,11] Olesen and colleagues described the landscape of correlations for 72 pathogen-antimicrobial combinations across U.S. states using outpatient antimicrobial prescription data covering 2011-2014.[3] The most positive significant correlations involved macrolides, fluoroquinolones, and cephalosporins. An analysis of five pathogen-antimicrobial combinations in eight U.S. hospitals showed that high antimicrobial use was not necessarily associated with high resistance.[11] For example, the use of anti-staphylococcal agents and percentage of methicillin-resistant *Staphylococcus* aureus (MRSA) were not correlated.

Few studies have investigated the potential impact of co-selection, i.e., the process that the use of one antimicrobial agent promotes the selection and persistence of resistance not only to that agent but also to others, on the use-resistance relationship.[12–14] In multivariate models for *S pneumoniae*, macrolide consumption explained as much variation in penicillin resistance as penicillin use, implying that macrolide exposure co-selected penicillin-resistant strains.[15] Pouwels and colleagues found that increased prescribing of amoxicillin in the community was associated not only with more amoxicillin-resistant *E coli* in urine isolates, but also with higher ciprofloxacin and trimethoprim resistance in those *E coli*.[13] These studies typically aggregate data at a high level (e.g., states, nations) and examine correlations between total antimicrobial consumption and overall resistance prevalence. Such analyses provide a broad view of the association but can mask within-group variability, may suffer from ecological fallacies, and are often subject to reverse confounding by not capturing the precise time lags between antimicrobial exposure and the development of resistance.[2]

Several other studies investigated the relationship between antimicrobial use and resistance on an individual-level.[16] In a case-control study, Weber and colleagues found that exposure to fluoroquinolones, specifically levofloxacin and ciprofloxacin, was a significant risk factor for the subsequent isolation of MRSA in hospitalized patients, but not for methicillin-susceptible *S aureus* (MSSA), highlighting the role of fluoroquinolones in co-selecting MRSA.[17] However, these do not typically account for the indirect effects on AMR due to transmission and thus fail to capture population-level dynamics – they may even yield associations that have the opposite sign from the effects at the population level.[18]

To our knowledge, no study has yet examined the impact of antimicrobial use on susceptibility patterns across multiple antimicrobials ('phenotypes') and multiple pathogens accounting for both individual-level and group-level effects. Under the guiding hypothesis that each antimicrobial exerts selection *for* the phenotypes that are resistant to it, we conducted hierarchical multinomial logistic regression analyses for four major community- and hospital-associated pathogens in the Veterans

Affairs Healthcare system (VAHS) in the United States (U.S.): *S aureus, E coli, K pneumoniae,* and *P aeruginosa.* We included data on antimicrobial susceptibility patterns from individual-level clinical isolates and facility-level antimicrobial prescribing from 138 Veterans Affairs Medical Centres (VAMCs) across all U.S. census regions from 2007-2021. By linking patient-level outcomes to facility-level antimicrobial use, we aimed to investigate how institutional prescribing practices shape the resistance patterns observed in patients. The scope of our study - the number of species, diversity of geographic sites, and long period of study - provides a unique opportunity to evaluate this question.

## Methods (1033 words)
*Study design and participants*

In this US nationwide retrospective cohort study, we analysed clinical microbiology data from patients admitted to all VA Medical Centres with acute care wards (either medical or surgical wards or intensive care units) from Feb 1, 2007, to Dec 31, 2021. We define the pre-COVID-19 period as Feb 1, 2007 till Dec 31, 2019 and the COVID-19 period as Jan 1, 2020 till Dec 31, 2021. For trend analyses of antimicrobial prescribing, we included 138 VAMS. For antimicrobial use-resistance analyses, we included facilities according to a patchwork approach (Table 1). The patient age was determined from the patient's date of birth. The biological sex of patients was determined from their birth certificates. Race and ethnicity were collected by self-report.

This study was approved by the University of Utah Institutional Review Board and the VA Salt Lake City Health Care System Research and Development Office, which waived patient consent because the project relied on retrospective analysis of existing patient records. The study followed the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guideline for cohort studies.

*Procedures*

Clinical diagnostic cultures were extracted from electronic health records, as previously described.[19] Our analysis only included results from clinically directed cultures, ordered to evaluate suspected infection. We defined a 30-day incident isolate as a clinical culture where no other clinical culture of the same species was identified in the previous 30 days and used it as a proxy measure for clinical infection incidence. When multiple species were recovered from the same sample or from different samples collected during the same hospitalisation, each incident isolate was separately counted in the analysis of a given species.

All specimens collected more than 3 days post-admission but before discharge were classified as hospital-onset and included in our analysis.

Antimicrobial susceptibility test (AST) results were used to identify whether a culture was resistant to a specific antimicrobial. Interpretation of ASTs was based on the reported minimum inhibitory concentrations and categorised into susceptible (S), intermediate (I), or resistant (R). We grouped intermediate and resistant to R in our analyses. Interpretation of AST results adhered to CLSI breakpoint revisions. We defined (resistance) phenotypes as the susceptibility profile of a bacterial isolate to a panel of key antimicrobials chosen based on their clinical relevance for first- and second-line treatment of the target pathogens (Table 1, appendix p.2 Table S2). An overview of pathogen-antimicrobial combinations and the respective phenotypes can be found in the appendix (section S4). We refered to isolates susceptible to all three key antimicrobial classes as susceptible isolates.

*Outcomes*
Our main outcomes were phenotypic incidence in the study population, facility-level inpatient antimicrobial prescribing rates, and regression coefficients obtained from fitting multinomial logistic regression models to datasets of the target antimicrobial-pathogen combinations. We defined phenotypic incidence as the number of incident isolates with a specific susceptibility profile per 1,000 admissions. We defined inpatient antimicrobial prescribing rates as the days of therapy (DOT) per 1,000 patient-days.

*Statistical Analysis*
For trends in inpatient antimicrobial prescribing and phenotypic incidence, we performed robust Poisson regression using generalized estimating equations (GEE).[20] Clustering by VAMC was modelled with an autoregressive correlation structure within a facility. We used calendar year as a continuous variable as the main exposure and the number of admissions as offset. We adjusted for major facility characteristics, including census region, facility complexity and rurality, and patient volume, and therefore, accounted for spatial variation and population density (appendix section S2). In addition, we estimated the multiplicative average annual percentage change (AAPC) based on the estimated marginalized time trend from our GEE analysis.

We fitted mixed-effects multinomial logistic regressions to link facility-level antimicrobial exposure to resistance patterns. For each pathogen, the outcome was the isolate's phenotype (i.e., susceptibility pattern to key antimicrobial classes). The fully susceptible phenotype (S-S-S) served as the reference. The primary exposure of interest was the cumulative facility-level antimicrobial DOT  during the preceding 14 days per 1,000 patient-days, abbreviated as *recent* prescribing for each drug class. To address potential ecological confounding, we adjusted for calendar year, community prevalence (measured by the incidence rate of  phenotypes collected within 3 days of admission during the previous 90 days), and facility characteristics (e.g., census region, facility complexity, facility rurality). We included random intercepts for each VA facility in the multinomial model to capture between-facility heterogeneity. Full methodological details are given in the appendix (section S2).

For some antimicrobial classes, such as fluoroquinolones, a substantial proportion of isolates did not have reported AST results, complicating the construction of susceptibility profiles. The incidence and proportion of these missing AST results varied over time, indicating selective reporting.[21] To address this issue, we applied a threshold-based *patchwork approach* in our main analysis. For each antimicrobial-pathogen combination and each calendar year, we included only those facilities where the proportion of missing AST results did not exceed 30% in each quarter of that year. By excluding facility–year combinations with excessive missing data, we minimized the likelihood that our findings would be skewed by selective reporting. As a result, the final dataset is a composite of facilities contributing data from different calendar years. We performed sensitivity analyses to evaluate alternative methods for handling missing AST results (section S3).

To assess the impact of variation in facility-level antimicrobial prescribing on the ability to recover true regression coefficients, we conducted a simulation analysis assuming the model was correctly specified (the model used in the simulation was the same used for fitting). We used a multinomial logistic regression model where the covariates were calendar time and facility-level antibiotic use. This analysis examined how these factors influence bias, confidence interval coverage, the envelope, and the average confidence interval width. More details can be found in the appendix (section S6).

**Role of the funding source**

**Results (1146 words)**

Overall, phenotypic incidence trends showed a general decline from 2007 to 2021, with only a few notable exceptions (Figure 1, appendix Table S5). For *S aureus, K pneumoniae,* and *P aeruginosa* the incidence of isolates resistant to all three key antimicrobial classes (R-R-R) declined from 2007 to 2021. Specifically, the incidence of *S aureus* isolates resistant to fluoroquinolones, ASBL, and macrolides declined with an AAPC of -9.5%, (95%CI: -11.6%, -7.3%; p-value<0.0001). The incidence of *K pneumoniae* isolates resistant to FQL, 3GC, and BL/BLI declined with an AAPC of -5.1% (95%CI: -9.8%, -0.2%; p-value = 0.0401). The incidence of *P aeruginosa* resistant to fluoroquinolones, BL/BLI, and carbapenems declined with an AAPC of -8.7% (95%CI: -12.8%, -4.5%; p-value < 0.0001) respectively. However, the incidence of *E coli* isolates resistant to fluoroquinolones, 3GC, and BL/BLIs increased from 2007 to 2021 with an AAPC of 3.4% (95%CI: 0.5%, 6.5%; p-value = 0.0204). The incidence of 3GC-resistant *E coli* isolates increased. In particular, the incidence of R-R-S increased with an AAPC of 4.6% (95%CI: 0.2%, 9.2%; p-value = 0.0421). The incidence of S-R-R had an increasing trend (AAPC: 2%, 95%CI: -1.3%, 5.5%; p-value = 0.2372). The incidence of *E coli* resistant to FQL and BL/BLI but susceptible to 3GC declined with an AAPC of -5.4% (95%CI: -7.3%, -3.5%; p-value < 0.0001). FQL-resistant *E coli* susceptible to both 3GC and BL/BLI declined with an AAPC of -8.1% (95%CI: -11.4%, -4.7%; p-value < 0.0001). The incidence of susceptible isolates declined from 2007 till 2021 for *S aureus, E coli,* and *P aeruginosa* with an AAPC of 3.8% (95%CI: -6%, -1.5%; p-value = 0.0012), -5.1% (95%CI: -6.8%, -3.4%; p-value < 0.0001), and -2.6% (95%CI: -4.9%, -0.2%; p-value = 0.031), respectively. For *K pneumoniae*, the incidence of susceptible isolates declined from 2007 to 2021 (AAPC: -5.5%, 95%CI: -7.1%, -3.9%; p-value < 0.0001)

Inpatient antimicrobial prescribing declined for most antimicrobial classes (Figure 2, appendix Table S18). The largest decline was estimated for FQL from 2007 to 2022 (AAPC: -8.4%, 95%CI: -9.1%, -7.7%; p-value < 0.0001). Carbapenem prescribing rates increased from 2007 to 2011 with an AAPC of 5.3% (95%CI: 3.1%, 7.6%; p-value < 0.0001) and subsequently declined from 2012 to 2022 (AAPC: -3.7%, 95%CI: -6.2%, -1.1%; p-value = 0.0062). BL/BLI prescribing rates stayed stable from 2007 till 2014 (AAPC: -0.1%, 95%CI: -0.8%, 0.6%; p-value = 0.7993). After a nationwide shortage of piperacillin/tazobactam in 2015, BL/BLI prescribing rates declined (AAPC: -2.3%, 95%CI: -3.9%, -0.7%; p-value = 0.0046). Prescribing rates increased for 3GC from 2007 to 2019 (AAPC: 2.4%, 95%CI: 1.3%, 3.5%; p-value < 0.0001) but subsequently declined during pandemic years 2020 to 2022 (AAPC: -5%, 95%CI: -7.7%, -2.2%; p-value = 0.0005). Prescribing rates of ASBLs and macrolides declined slightly and remained stable prior to the COVID-19 pandemic (2007-2019) with AAPCs of -1% (95%CI: -1.7%, -0.2%; p-value = 0.0103) and -0.1% (95%CI: -1%, 0.9%; p-value = 0.8488), respectively. ASBL prescribing rates increased during COVID-19 pandemic years (2020-2022) with an AAPC of 4.6% (95%CI: 1.5%, 7.8%; p-value = 0.0038) whereas prescribing of macrolides declined (AAPC:-17.9%, 95%CI: -21%, -14.7%; p-value < 0.0001).

Our analysis relating facility-level antimicrobial use and resistance phenotypes revealed a consistent positive association between recent FQL use and the relative odds of FQL resistance across all four target pathogens (Figure 3). Specifically, point estimates for recent FQL prescribing indicated an increased odds of isolating FQL-resistant phenotypes, with confidence intervals excluding the null effect in 11 out of 13 cases. Among *S aureus* isolates, the strongest association

was estimated for FQL-resistant MRSA (R-R-S) isolates, which had an odds ratio of 1.0041 (95% CI: 1.0006, 1.0076). This result suggests that for an extra 14-day course of fluoroquinolone treatment (per 1,000 patient days in the preceding 14 days), we expect about a 5.9% (=$1.0041^{14}$-1) increase in odds of isolating a fluoroquinolone-resistant, macrolide-susceptible MRSA strain. Macrolide prescribing was linked to higher odds of isolating FQL-susceptible, MACR-resistant MRSA (S-R-R; odds ratio = 1.0050, 95%CI: 1.00, 1.0100). ASBL prescribing did not increase the odds of ASBL resistance for either of the studied phenotypes. In fact, ASBL prescribing was associated with a reduction in the odds of fluoroquinolone-resistant MRSA (odds ratio = 0.9912, 95%CI: 0.9834, 0.9990).

For *E coli*, the largest increase in odds was estimated for isolates resistant to fluoroquinolones but susceptible to 3GC and BL/BLIs (Figure 3B, R-S-S) and for isolates resistant to both fluoroquinolones and BL/BLI (Figure 3B, R-S-R). In *K pneumoniae,* the largest odds ratio was estimated for isolates resistant to both fluoroquinolones and BL/BLIs (Figure 3C, R-S-R, 1.0061, 95%CI: 1.0018, 1.0105). For *P aeruginosa*, recent FQL prescribing was associated with an odds ratio of 1.0028 (95%CI: 1.0008, 1.0047) for phenotypes resistant only to FQL (Figure 3D, R-S-S) and an odds ratio of 1.0021 (95%CI: 0.9997, 1.0045) for the phenotypes resistant to all three key antimicrobial classes.

For both *E coli,* recent use of 3GC increased the odds of isolates resistant to 3GC and BL/BLI but susceptible to FQLs (S-R-R, odds ratio: 1.0051, 95%CI: 1.0013, 1.009). We did not find an association between 3GC use and isolates resistant to both 3GC and FQLs (R-R-R and R-R-S phenotypes). Similarly, for *K pneumoniae*, recent 3GC use was associated with an increase in odds of MDR isolates resistant to both 3GC and BL/BLI (S-R-R, odds ratio: 1.0029, 95%CI: 0.9999, 1.0060) but not for XDR isolates additionally resistant to fluoroquinolones (R-R-R). For both Enterobacterales species, recent use of BL/BLI was associated with an increase in odds of resistant isolates  (S-S-R, S-R-R, R-S-R phenotypes, appendix Table S10, S13 ), except for isolates resistant to all three key antimicrobial classes (R-R-R).

For *P aeruginosa*, recent antipseudomonal CPM prescribing was associated with an increased odds of isolates resistant to CPM. The largest increase in odds was estimated for CPM-resistant isolates susceptible to both FQL and 3GC (S-S-R, odds ratio: 1.0147, 95% CI: 1.0090, 1.0204), followed by XDR *P aeruginosa* isolates (R-R-R, odds ratio: 1.01, 95% CI: 1.0056, 1.0143) and MDR *P aeruginosa* isolates resistant to FQLs and CPMs (R-S-R, odds ratio: 1.0097, 95%CI: 1.0045, 1.0150). For
For most pathogen-phenotype combinations, the importation of phenotypes by community-onset isolates was significantly associated with an increase in odds of isolates with that specific phenotype (appendix section S4).

To evaluate how dataset characteristics affect regression coefficient estimation in multinomial logistic regression, we conducted a simulation analysis under a correctly specified model (Figure 4, appendix section S6). We focused on how decreased variability in antimicrobial prescribing influences bias, coverage, the envelope (range) of estimated coefficients, and confidence interval precision. Although a smaller variance in antimicrobial prescribing (Drug 2 and 3) did not affect the median bias, it increased the bias variance (Figure 4A). Furthermore, as the variability in antimicrobial prescribing declined, both the envelope and the average width of the 95% confidence intervals increased (Figure 4C), reflecting greater uncertainty in the coefficient estimates. The coverage, the proportion of 95% confidence intervals containing the true coefficient, remained unchanged.

**Discussion (1004 words)**

In this nationwide study, we observed notable shifts in phenotypic incidence trends among four major pathogens in the VAHS from 2007 to 2022, in parallel with changes in antimicrobial prescribing. Furthermore, we found that facility-level antimicrobial prescribing was significantly associated with resistance patterns at the individual-level for most pathogen-antimicrobial combinations.

A particularly notable finding was the broad decline in FQL resistance across all four pathogens and eleven corresponding phenotypes, except for *E coli* resistant to both FQL and 3GC. These observations were supported by significant associations between recent facility-level FQL prescribing and FQL resistance for all four target pathogens. Nevertheless, the persistence of co-resistance to fluoroquinolones and 3GC in *E coli* isolates, despite an overall decline in fluoroquinolone prescribing, underscores the complexity of resistance dynamics. In fact, overall 3GC prescribing increased over the study period, potentially as a replacement for fluoroquinolones, and higher recent facility-level 3GC exposure was generally associated with an increase in odds of phenotypes resistant to 3GCs. However, this relationship was less pronounced in isolates already resistant to fluoroquinolones, though the estimates showed considerable uncertainty. In addition, while the incidence of *E coli* resistant to both 3GC and BL/BLI showed an increasing trend, the incidence of BL/BLI-resistant *E coli* (susceptible to 3GC) declined. Similarly, the incidence of *E coli* resistant to FQL but susceptible to 3GC declined, suggesting that co-selection by 3GC may help maintain or even drive FQL and BL/BLI resistance in MDR *E coli*. These findings suggest while reductions in antimicrobial prescribing may lead to a decrease in corresponding resistance patterns, reductions in prescribing in one antimicrobial class may be offset by increased prescribing of another, potentially leading to collateral resistance. Ongoing surveillance is therefore crucial to detect and address evolving co-resistance dynamics. Given that once resistance emerges, large reductions in consumption are required to meaningfully reduce resistance levels,[22] early and multifaceted stewardship and infection control interventions are essential to controlling AMR.

Prescribing to carbapenems and BL/BLs was also associated with subsequent resistance in *P aeruginosa,* with antipseudomonal carbapenems showing higher odds ratios than fluoroquinolones. These results align with earlier reports linking carbapenem use to extensively-resistant (XDR) *P aeruginosa* infections, and fluoroquinolone, cephalosporin, and carbapenem use to MDR or XDR *P aeruginosa* infections.[23,24] In addition, we observed a decline in the incidence of all studied phenotypes in this study, aligning with the previously described decline in hospital-associated infections in the VAHS and the decline of MDR and XDR *P aeruginosa* in other regions.[21] The declining trends were paralleled with reductions in prescribing to FQLs, CPMs and BL/BLIs. While previous studies have linked the restriction of CPM use to a decline in CPM resistance incidence rates,[25] the relative contribution of each antimicrobial class to these declines remains unclear, warranting further research to disentangle their individual impacts on resistance selection and pathogen fitness.

Our results for *S aureus* suggest that MRSA incidence may not be driven by prescribing of anti-staphylococcal beta-lactams but rather by prescribing of fluoroquinolones and macrolides, echoing previous findings that linked fluoroquinolone use but not beta-lactam use to MRSA colonization.[17,26–28] Restricting fluoroquinolone use was linked to a reduction in MRSA isolation rates in several studies.[cite] In addition, the reverse was observed in a 10-year time-series analysis where MRSA rates increased upon reintroduction of fluoroquinolones.[Parenti] This pattern, together with evidence that fluoroquinolones promote the loss of MSSA colonization more than other anti-MSSA agents,[29] suggest that fluoroquinolones may promote MRSA selection

through ecological disruption, eradicating MSSA strains and creating a niche for resistant strains to proliferate.[30] The lack of association between anti-staphylococcal beta-lactams and MRSA incidence in our study may reflect the distinct evolutionary pathway of methicillin resistance. Historically, penicillin use – not methicillin – has been implicated as the primary driver of mecA acquisition in *S aureus*.[31] Our study underscores the nuanced roles different antimicrobial classes play in shaping pathogen dynamics.

Our study has several limitations. First, although our model explicitly accounts for prior antimicrobial exposure and includes multiple facility-level characteristics to mitigate confounding, we cannot rule out residual confounding, including reverse causation. For example, facilities with high prevalence of MRSA may refrain from the use of antimicrobials known to be associated with MRSA (and the other way around) which could paradoxically link higher use of anti-staphylococcal beta-lactams to lower MRSA prevalence. Second, although we incorporated a 14-day lag to address reverse causality, this may not fully capture such dynamics. Third, we included only inpatient antimicrobial prescribing into our model. For many pathogens, community-based prescribing may contribute significantly to selection pressure and subsequent hospital importation of resistant organisms. Fourth, we classified isolates as hospital-onset if they were collected at least 72 hours after admission, which can misclassify some community-acquired infections. Fifth, our simulation analysis suggests that variability in previous antimicrobial prescribing is crucial for precisely estimating regression coefficients. For antimicrobial classes with limited variability in their prescribing, coefficient estimates can carry high uncertainty, potentially explaining some of our null findings. Sixth, while phenotypes can be used as proxies for bacterial lineages, future studies incorporating whole genome sequencing alongside phenotypic profiles are needed to more clearly elucidate the relationships between antimicrobial use and microbial ecology. Finally, the patient population in our study is limited to enrolled veterans in the USA with access to the VA Healthcare System. The veteran population differs from the general population in their health characteristics, including their demographics, underlying health conditions, exposures, and health-care use patterns. However, our study included data from up to 99 medical facilities with varying complexity levels, from different geographical regions in the USA, and from more than 15 years.

Overall, our findings underscore the complexity of antimicrobial selection pressure and its variable effects depending on drug class, pathogen, co-resistance, and resistance mechanisms. We highlight how reductions in one antimicrobial class can inadvertently drive reliance on – and potential resistance to – another. To effectively combat AMR, stewardship efforts must be comprehensive, targeting multiple antimicrobial classes in tandem rather than in isolation. Such coordinated strategies, coupled with robust surveillance and early interventions, are essential to contain the rise of multidrug-resistance and preserve the efficacy of existing therapies.

**Data sharing**
Individual-level patient data cannot be provided due to Veteran Affairs privacy practices. Artificial data that represents the original data will be provided along with a data dictionary that defines each field in the dataset and supporting documentation (statistical and analytic code) are published on Github (https://github.com/tm-pham/mind_aim2-2_AMR).

(IIR 21–273) and for two studies from BioMerieux Clinical (IRB_00170297; IRB_00140336). All other authors declare no competing interests.

**Acknowledgments**

This work was supported by the US Centers for Disease Control and Prevention (Modeling and Simulation to Support Epidemiological Decision-Making in Healthcare Settings, Modeling Infectious Diseases in Healthcare Program; U01CK000585). MS was supported by the Agency for Healthcare Research and Quality (R01HS025175) and the Department of Veterans Affairs (1I50HX002731–01). We thank the Department of Veterans Affairs for the supported infrastructure and data resources. The views expressed in this article are those of the authors and do not necessarily represent the position or policy of the Department of Veterans Affairs, the US Centers for Disease Control and Prevention, the US Government, or any of the affiliated institutions.

**Table 1. Descriptive statistics of clinical cultures included in the multinomial logistic regression analysis by organism, Feb 1, 2007, to Dec 31, 2021.** Patient age was determined from the date of birth. The biological sex of patients was determined from their birth certificates. Race and ethnicity were collected by self-report. Only the most common groups are displayed in this table.

| | Gram-positive cocci | Enterobacterales | | Gram-negative non-fermenter |
| --- | --- | --- | --- | --- |
| | *Staphylococcus aureus* | *Escherichia coli* | *Klebsiella pneumoniae* | *Pseudomonas aeruginosa* |
| Key antimicrobial classes | Fluoroquinolones Antistaphylococcal Beta-lactams (ASBL) Macrolides | Fluoroquinolones 3$^{rd}$ generation Cephalosporins (3GC) Beta-lactam/Beta-lactamase inhibitors (BL/BLI) | Fluoroquinolones 3$^{rd}$ generation Cephalosporins (3GC) Beta-lactam/Beta-lactamase inhibitors (BL/BLI) | Fluoroquinolones Beta-lactam/Beta-lactamase inhibitors (BL/BLI) Carbapenems |
| Incident isolates, n | 17,722 | 25,149 | 22,477 | 19,299 |
| Number of facilities | 84 | 99 | 95 | 96 |
| **Sex/Age, n (%)** | | | | |
| Male | 17258 (97.4%) | 23868 (94.9%) | 21694 (96.5%) | 18862 (97.7%) |
| Female | 464 (2.6%) | 1281 (5.1%) | 783 (3.5%) | 437 (2.3%) |
| Median age (IQR), years | 68 (61-77) | 70 (63-79) | 70 (63-78) | 70 (63-78) |
| **Race and ethnicity, n (%)** | | | | |
| White | 13085 (73.8%) | 17035 (67.7%) | 15033 (66.9%) | 13342 (69.1%) |
| Black or African American | 3381 (19.1%) | 6412 (25.5%) | 6014 (26.8%) | 4650 (24.1%) |
| Hispanic or Latino | 1636 (9.2%) | 2050 (8.2%) | 2338 (10.4%) | 1978 (10.2%) |
| **Culture sites, n (%)** | | | | |
| Blood, n (%) | 2317 (13.1%) | 1769 (7%) | 2339 (10.4%) | 876 (4.5%) |
| Urine, n (%) | 667 (3.8%) | 14410 (57.3%) | 10220 (45.5%) | 7487 (38.8%) |
| Respiratory, n (%) | 7840 (44.2%) | 3648 (14.5%) | 6322 (28.1%) | 6995 (36.2%) |
| Other, n (%) | 6898 (38.9%) | 5322 (21.2%) | 3596 (16%) | 3941 (20.4%) |

**Figure 1. Phenotypic time trends for hospital-onset isolates of four target pathogens in the Veterans Affairs Healthcare Administration from 2007-2021.** Patchwork data was used for the analysis. (A) Points represent the incidence in infections with the respective phenotype. Lines and grey bands are linear regression curves and corresponding 95% CIs. (B) AAPC obtained from time trend analyses using generalised estimating equations for the respective phenotypic incidence. The interaction with the COVID-19 period was tested and a separate time trend estimate is reported if the interaction term was significant (p-value < 0.05). An AAPC greater than zero indicates an increasing trend and an AAPC less than zero indicates a declining trend. AAPC=average annual percentage change.

**Figure 2. Antimicrobial prescribing time trends in the Veterans Affairs Healthcare Administration from 2007-2022 for key antimicrobial classes.** (A) Bar plots show the overall antimicrobial prescribing rates, measured as days of therapy per 1,000 patient days, from 2007 till 2022 in 138 VA medical centres for key antimicrobial classes. (B) AAPC obtained from time trend analyses using generalised estimating equations for antimicrobial classes depicted in A. The interaction with the COVID-19 period was tested and a separate time trend estimate is reported if the interaction term was significant (p-value < 0.05). An AAPC greater than zero indicates an increasing trend and an AAPC less than zero indicates a declining trend. AAPC=average annual percentage change.

**Figure 3. Multinomial logistic regression results for four target pathogens.** (A) Coefficient estimates and confidence intervals (80% and 95%) for pathogen-specific key antimicrobial classes. *S aureus:* fluoroquinolones, anti-staphylococcal beta-lactams, macrolides. (B) *E coli:* fluoroquinolones (FQL), 3rd generation cephalosporins (3GC), beta-lacatam/beta-lactamase inhibitors. (C) *K pneumoniae:* fluoroquinolones, 3rd generation cephalosporins, beta-lacatam/beta-lactamase inhibitors. (D) *P aeruginosa:* fluoroquinolones, beta-lactam/beta-lactamase inhibitors, carbapenems. Estimates represent the odds ratio with respect to the reference categories. For all analyses, the phenotype susceptible to all key antimicrobial classes was used as reference.

**Figure 4. Impact of variability in facility-level antimicrobial prescribing on regression coefficient estimation on bias, coverage, envelope and confidence interval precision.** Three prescribing distribution of drug classes were simulated with large (Drug 1), medium (Drug 2), and small variance (Drug 3) based on log-normal distribution with parameters described in the appendix (section S6). The results were summarized across 100 simulated data sets. (A) Boxplot and distribution of bias in regression coefficient estimates, defined as the difference between the estimate and the true coefficient. (B) Bar plots of coverage of 95% confidence intervals. This panel illustrates the proportion of simulation runs in which the true regression coefficient is captured by the estimated 95% confidence intervals. (C) Envelope (lines, left y-axis) and Average Confidence Interval Width (bar plots, right y-axis). The envelope (range) of estimated regression coefficients is shown as line intervals (left y-axis) and the average width of the 95% confidence intervals is represented by bar plots (right y-axis).

# References

Lipsitch M, Samore MH. Antimicrobial Use and Antimicrobial Resistance: A Population Perspective - Volume 8, Number 4—April 2002 - Emerging Infectious Diseases journal - CDC. *Emerg Infect Dis* 2002; **8**: 347–54.

Schechner V, Temkin E, Harbarth S, Carmeli Y, Schwaber MJ. Epidemiological Interpretation of Studies Examining the Effect of Antimicrobial Usage on Resistance. *Clin Microbiol Rev* 2013; **26**: 289.

Olesen SW, Barnett ML, Macfadden DR, *et al.* The distribution of antimicrobial use and its association with antimicrobial resistance. *Elife* 2018; **7**. DOI:10.7554/ELIFE.39435.

Abejew AA, Wubetu GY, Fenta TG. Relationship between Antimicrobial Consumption and Resistance: A Systematic Review. *Canadian Journal of Infectious Diseases and Medical Microbiology* 2024; **2024**: 9958678.

Bell BG, Schellevis F, Stobberingh E, Goossens H, Pringle M. A systematic review and meta-analysis of the effects of antimicrobial consumption on antimicrobial resistance. *BMC Infect Dis* 2014; **14**: 1–25.

Laffont-Lozes P, Larcher R, Salipante F, *et al.* Usefulness of dynamic regression time series models for studying the relationship between antimicrobial consumption and bacterial antimicrobial resistance in hospitals: a systematic review. *Antimicrob Resist Infect Control* 2023; **12**: 1–10.

Goossens H, Ferech M, Vander Stichele R, Elseviers M. Outpatient antimicrobial use in Europe and association with resistance: A cross-national database study. *Lancet* 2005; **365**: 579–87.

Willemsen I, Bogaers-Hofman D, Winters M, Kluytmans J. Correlation between antimicrobial use and resistance in a hospital: Temporary and ward-specific observations. *Infection* 2009; **37**: 432–7.

Van De Sande-Bruinsma N, Grundmann H, Verloo D, *et al.* Antimicrobial Drug Use and Resistance in Europe. *Emerg Infect Dis* 2008; **14**: 1722.

Rahman S, Kesselheim AS, Hollis A. Persistence of resistance: a panel data analysis of the effect of antimicrobial usage on the prevalence of resistance. *The Journal of Antimicrobials 2023 76:5* 2023; **76**: 270–8.

Monnet DL, Archibald LK, Phillips L, *et al.* Antimicrobial Use and Resistance in Eight US Hospitals: Complexities of Analysis and Modeling. *Infect Control Hosp Epidemiol* 1998; **19**: 388–94.

Pouwels KB, Freeman R, Muller-Pebody B, *et al.* Association between use of different antimicrobials and trimethoprim resistance: going beyond the obvious crude association. *Journal of Antimicrobial Chemotherapy* 2018; **73**: 1700–7.

Pouwels KB, Muller-Pebody B, Smieszek T, Hopkins S, Robotham J V. Selection and co-selection of antimicrobial resistances among Escherichia coli by antimicrobial use in primary care: An ecological analysis. *PLoS One* 2019; **14**: e0218134.

Doan T, Worden L, Hinterwirth A, *et al.* Macrolide and Nonmacrolide Resistance with Mass Azithromycin Distribution. *New England Journal of Medicine* 2020; **383**: 1941–50.

García-Rey C, Aguilar L, Baquero F, Casal J, Dal-Ré R. Importance of local variations in antimicrobial consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae. *J Clin Microbiol* 2002; **40**: 159–64.

Costelloe C, Metcalfe C, Lovering A, Mant D, Hay AD. Effect of antimicrobial prescribing in primary care on antimicrobial resistance in individual patients: systematic review and meta-analysis. *BMJ* 2010; **340**: 1120.

Weber SG, Gold HS, Hooper DC, Karchmer AW, Carmeli Y. Fluoroquinolones and the Risk for Methicillin-resistant Staphylococcus aureus in Hospitalized Patients - Volume 9, Number 11—November 2003 - Emerging Infectious Diseases journal - CDC. *Emerg Infect Dis* 2003; **9**: 1415–22.

Lipsitch M, Bergstrom CT, Levin BR. The epidemiology of antimicrobial resistance in hospitals: Paradoxes and prescriptions. *Proceedings of the National Academy of Sciences* 2000; **97**: 1938–43.

Jones M, Duvall SL, Spuhl J, Samore MH, Nielson C, Rubin M. Identification of methicillin-resistant staphylococcus aureus within the nations veterans affairs medical centers using natural language processing. *BMC Med Inform Decis Mak* 2012; **12**: 1–8.

Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. *Biometrika* 1986; **73**: 13–22.

Pham TM, Zhang Y, Nevers M, *et al.* Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007–22). *Lancet Infect Dis* 2024; **0**. DOI:10.1016/S1473-3099(24)00416-X.

Austin DJ, Kristinsson KG, Anderson RM. The relationship between the volume of antimicrobial consumption in human communities and the frequency of resistance. *Proc Natl Acad Sci U S A* 1999; **96**: 1152.

Raman G, Avendano EE, Chan J, Merchant S, Puzniak L. Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: A systematic review and meta-analysis. *Antimicrob Resist Infect Control* 2018; **7**: 1–14.

Sulis G, Sayood S, Katukoori S, *et al.* Exposure to World Health Organization's AWaRe antimicrobials and isolation of multidrug resistant bacteria: a systematic review and meta-analysis. *Clinical Microbiology and Infection* 2022; **28**: 1193–202.

Pakyz AL, Oinonen M, Polk RE. Relationship of Carbapenem Restriction in 22 University Teaching Hospitals to Carbapenem Use and Carbapenem-Resistant Pseudomonas aeruginosa. *Antimicrob Agents Chemother* 2009; **53**: 1983.

LeBlanc L, Pépin J, Toulouse K, *et al.* Fluoroquinolones and Risk for Methicillin-Resistant Staphylococcus aureus, Canada. *Emerg Infect Dis* 2006; **12**: 1398.

Couderc C, Jolivet S, Thiébaut ACM, *et al.* Fluoroquinolone Use Is a Risk Factor for Methicillin-Resistant Staphylococcus aureus Acquisition in Long-term Care Facilities: A Nested Case-Case-Control Study. *Clinical Infectious Diseases* 2014; **59**: 206–15.

Hori S, Sunley R, Tami A, Grundmann H. The Nottingham Staphylococcus aureus population study: Prevalence of MRSA among the elderly in a university hospital. *Journal of Hospital Infection* 2002; **50**: 25–9.

Couderc C, Thiébaut ACM, Lawrence C, *et al.* Fluoroquinolone Impact on Nasal Methicillin-Resistant and Methicillin-Sensitive Staphylococcus aureus Colonization Durations in Neurologic Long-Term-Care Facilities. *Antimicrob Agents Chemother* 2015; **59**: 7621.

Venezia RA, Domaracki BE, Evans AM, Preston KE, Graffunder EM. Selection of high-level oxacillin resistance in heteroresistant Staphylococcus aureus by fluoroquinolone exposure. *Journal of Antimicrobial Chemotherapy* 2001; **48**: 375–81.

Harkins CP, Pichon B, Doumith M, *et al.* Methicillin-resistant Staphylococcus aureus emerged long before the introduction of methicillin into clinical practice. *Genome Biol* 2017; **18**: 1–11.